Earnings
MiMedx CEO Won't Put A Date On Sanara Closing After FTC Second Request
The deal was aimed at an October close, and the delay has started a ticking fee on a $300 million term loan commitment.
MDXG
MiMedx Group (MDXG) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
MiMedx CEO Says Wound Care's Bottom Is Hard To Call, Sees 2027 Looking Like 2026
Joseph Capper says the company is "only three quarters into this reset" as wound sales fell 71% to $22 million.
SEC Filings
MiMedx Breached Its Bank Covenants While Lining Up $300 Million In Debt For The Sanara Deal
Lenders waived the Event of Default, but the revolver is frozen and the $350 million Sanara purchase faces an FTC Second Request.
Deals
MiMedx Sales Fall 45% To $62 Million As FTC Review Holds Up Sanara Deal
The wound-care maker's Wound sales fell 71% in the third quarter while Surgical rose 9%, and it landed a $25 million patent license.
Deals
MiMedx And Sanara Each Get An FTC Second Request, Stretching The Merger's Antitrust Clock
The FTC wants more documents from both companies, so the antitrust waiting period on the planned deal now depends on when they comply.